{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:58:44Z","timestamp":1790150324580,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["40007488"],"award-info":[{"award-number":["40007488"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["G016221N"],"award-info":[{"award-number":["G016221N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["F2023\/IOF-ConcepTT\/033"],"award-info":[{"award-number":["F2023\/IOF-ConcepTT\/033"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["11E3123N"],"award-info":[{"award-number":["11E3123N"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["BOF23\/GOA\/029"],"award-info":[{"award-number":["BOF23\/GOA\/029"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["BOF\/IOP\/2022\/ 033"],"award-info":[{"award-number":["BOF\/IOP\/2022\/ 033"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["#BOF22\/DOC\/012"],"award-info":[{"award-number":["#BOF22\/DOC\/012"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["IMMUNO-FER-GUARD\\u2019 F2023\/IOF-ConcepTT\/106"],"award-info":[{"award-number":["IMMUNO-FER-GUARD\\u2019 F2023\/IOF-ConcepTT\/106"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"UGent","doi-asserted-by":"publisher","award":["BOF\/IOP01\/O3618"],"award-info":[{"award-number":["BOF\/IOP01\/O3618"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trecan.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:34:43Z","timestamp":1758112483000},"page":"1145-1154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CX3CL1: a key switch of cell death immunogenicity"],"prefix":"10.1016","volume":"11","author":[{"given":"Robin","family":"Demuynck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Naessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-2047","authenticated-orcid":false,"given":"Dmitri V.","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.08.008_bb0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/385640a0","article-title":"A new class of membrane-bound chemokine with a CX3C motif","volume":"385","author":"Bazan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.08.008_bb0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/42491","article-title":"Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation","volume":"387","author":"Pan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.08.008_bb0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1471-4159.2009.06475.x","article-title":"Multi-targeted neuroprotection by the HSV-2 gene ICP10PK includes robust bystander activity through PI3-K\/Akt and\/or MEK\/ERK-dependent neuronal release of vascular endothelial growth factor and fractalkine","volume":"112","author":"Laing","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.trecan.2025.08.008_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41467-023-44619-8","article-title":"Apoptosis-mediated ADAM10 activation removes a mucin barrier promoting T cell efferocytosis","volume":"15","author":"Drexhage","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.08.008_bb0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/membranes13080720","article-title":"Breakdown of phospholipid asymmetry triggers ADAM17-mediated rescue events in cells undergoing apoptosis","volume":"13","author":"Sperrhacke","year":"2023","journal-title":"Membranes"},{"key":"10.1016\/j.trecan.2025.08.008_bb0035","doi-asserted-by":"crossref","first-page":"37993","DOI":"10.1074\/jbc.M106434200","article-title":"Tumor necrosis factor-\u03b1-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)","volume":"276","author":"Garton","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2025.08.008_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-016-0659-7","article-title":"Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes","volume":"13","author":"O\u2019Sullivan","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.trecan.2025.08.008_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1183795","article-title":"A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1)","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.trecan.2025.08.008_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752860","article-title":"The clinical implications and molecular mechanism of CX3CL1 expression in urothelial bladder cancer","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0055","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1186\/s12885-022-10302-2","article-title":"CX3CL1 promotes cell sensitivity to ferroptosis and is associated with the tumor microenvironment in clear cell renal cell carcinoma","volume":"22","author":"Gong","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0060","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.3390\/ijms21103723","article-title":"Fractalkine\/CX3CL1 in neoplastic processes","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.08.008_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cbf.3278","article-title":"Fractalkine\/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT\/NF-\u03baB cascade in pancreatic cancer cells","volume":"35","author":"Wang","year":"2017","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.trecan.2025.08.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100069","article-title":"CX3CL1 as potential immunotherapeutic tool for bone metastases in lung cancer: a preclinical study","volume":"6","author":"Cohen","year":"2022","journal-title":"Adv. Cancer Biol. Metastasis"},{"key":"10.1016\/j.trecan.2025.08.008_bb0075","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.08.008_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237715","article-title":"The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy","volume":"14","author":"Chaudhri","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13048-019-0517-1","article-title":"Hypoxia-inducible factor-1\u03b1 induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells","volume":"12","author":"Singh","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.trecan.2025.08.008_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-pathmechdis-031521-023557","article-title":"Orchestration of collective migration and metastasis by tumor cell clusters","volume":"18","author":"Yamamoto","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101130","article-title":"The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer","volume":"60","author":"Seitz","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.trecan.2025.08.008_bb0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/cvr\/cvm067","article-title":"Activation of fractalkine\/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A\/KDR and reverses hindlimb ischaemia","volume":"78","author":"Ryu","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.trecan.2025.08.008_bb0105","doi-asserted-by":"crossref","first-page":"H2836","DOI":"10.1152\/ajpheart.00113.2006","article-title":"Fractalkine stimulates angiogenesis by activating the Raf-1\/MEK\/ERK- and PI3K\/Akt\/eNOS-dependent signal pathways","volume":"291","author":"Lee","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.intimp.2015.04.010","article-title":"Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially","volume":"26","author":"Zhao","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2320951","article-title":"Lactate\/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer","volume":"13","author":"Su","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2025.08.008_bb0125","article-title":"Metabolic-immune suppression mediated by the SIRT1-CX3CL1 axis induces functional enhancement of regulatory T cells in colorectal carcinoma","volume":"12","author":"Zi","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.trecan.2025.08.008_bb0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7150\/jca.47022","article-title":"Regulation and biological functions of the CX3CL1-CX3CR1 axis and its relevance in solid cancer: a mini-review","volume":"12","author":"Rivas-Fuentes","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0135","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255884","article-title":"Plasma fractalkine contributes to systemic myeloid diversity and PD-L1\/PD-1 blockade in lung cancer","volume":"24","author":"Bocanegra","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.trecan.2025.08.008_bb0140","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.2000987","article-title":"Fractalkine elicits chemotactic, phenotypic, and functional effects on CX3CR1+CD27\u2212 NK cells in obesity-associated cancer","volume":"207","author":"Mylod","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-024-02097-6","article-title":"YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment","volume":"23","author":"Yang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110243","article-title":"The endothelial diapedesis synapse regulates transcellular migration of human T lymphocytes in a CX3CL1- and SNAP23-dependent manner","volume":"38","author":"Schoppmeyer","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.08.008_bb0155","first-page":"5259","article-title":"The chemokine CX3CL1 promotes trafficking of dendritic cells through inflamed lymphatics","volume":"126","author":"Johnson","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.trecan.2025.08.008_bb0160","article-title":"Mesenchymal stem cells elicits anti-PD1 immunotherapy by targeted delivery of CX3CL1","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106443","article-title":"CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies","volume":"26","author":"Trinh","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.trecan.2025.08.008_bb0170","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.7150\/thno.32543","article-title":"The miR-561-5p\/CX3CL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CX3CR1+ natural killer cells infiltration","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.08.008_bb0175","first-page":"L1230","article-title":"Fractalkine\/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids","volume":"287","author":"Sukkar","year":"2004","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.trecan.2025.08.008_bb0180","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.4049\/jimmunol.0903212","article-title":"Characterization of synergistic induction of CX3CL1\/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1","volume":"184","author":"Matsumiya","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0185","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jleuko\/qiad097","article-title":"Chemokine Cxcl1\u2013Cxcl2 heterodimer is a potent neutrophil chemoattractant","volume":"114","author":"Sawant","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12865-021-00469-x","article-title":"Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus","volume":"22","author":"Zeng","year":"2021","journal-title":"BMC Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1189\/jlb.0907652","article-title":"Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration","volume":"84","author":"Popovic","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.10816","article-title":"Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells","volume":"103","author":"Guo","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0205","first-page":"3722","article-title":"Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53","volume":"60","author":"Shiraishi","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.08.008_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/mco.2012.30","article-title":"Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo","volume":"1","author":"Kee","year":"2013","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0215","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.gt.3302959","article-title":"Gene therapy with CX3CL1\/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma","volume":"14","author":"Tang","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.trecan.2025.08.008_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1396349","article-title":"CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity","volume":"15","author":"Naessens","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97828","article-title":"CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy","volume":"3","author":"Yan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2025.08.008_bb0230","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.4049\/jimmunol.167.9.5004","article-title":"Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation","volume":"167","author":"Magnus","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0235","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jmor.10161","article-title":"Mechanisms of internalization of apoptotic and necrotic L929 cells by a macrophage cell line studied by electron microscopy","volume":"258","author":"Krysko","year":"2003","journal-title":"J. Morphol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0240","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2119\/2007-00019.Miksa","article-title":"Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages","volume":"13","author":"Miksa","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.trecan.2025.08.008_bb0245","first-page":"4877","article-title":"Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.trecan.2025.08.008_bb0250","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/cdd.2016.5","article-title":"Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation","volume":"23","author":"Garg","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.trecan.2025.08.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0260","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2025.08.008_bb0265","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2025.08.008_bb0270","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.7150\/thno.42243","article-title":"Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity","volume":"10","author":"Sethuraman","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.08.008_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176191","article-title":"Intranasal exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: role of mTORC1 in immunogenic and tolerogenic cell demise","volume":"961","author":"Zaky","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0280","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nri3607","article-title":"Apoptotic cell clearance: basic biology and therapeutic potentia","volume":"14","author":"Poon","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0285","article-title":"Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation","volume":"62","author":"Kota","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.trecan.2025.08.008_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100283","article-title":"A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis","volume":"10","author":"Tanaka","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.trecan.2025.08.008_bb0295","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0300","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241207","article-title":"Early transcriptional effects of inflammatory cytokines reveal highly redundant cytokine networks","volume":"222","author":"Lee","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2025.08.008_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-36667-4_1","article-title":"CX3CL1 signaling in the tumor microenvironment","volume":"1231","author":"Conroy","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0310","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/0008-5472.CAN-12-3828","article-title":"CX3CL1 promotes breast cancer via transactivation of the EGF pathway","volume":"73","author":"Tard\u00e1guila","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.08.008_bb0315","doi-asserted-by":"crossref","first-page":"S1587","DOI":"10.1245\/s10434-015-4804-9","article-title":"TGF beta1 expression correlates with survival and tumor aggressiveness of prostate cancer","volume":"22","author":"Wu","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0320","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2017.00868","article-title":"TGF-\u03b21 downregulates the expression of CX3CR1 by inducing miR-27a-5p in primary human NK cells","volume":"8","author":"Regis","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.08.008_bb0325","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.08.008_bb0330","first-page":"1","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2025.08.008_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001369","article-title":"Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity","volume":"8","author":"Efimova","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0340","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.trecan.2024.01.013","article-title":"Immunogenicity of ferroptosis in cancer: a matter of context?","volume":"10","author":"Catanzaro","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.08.008_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003430","article-title":"Immunogenic ferroptosis and where to find it?","volume":"9","author":"Demuynck","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:20:47Z","timestamp":1765297247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2405803325002067"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.08.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CX3CL1: a key switch of cell death immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}